Value through Innovation27 February 2015

Boehringer Ingelheim Press Releases

See the latest Boehringer Ingelheim news releases. To quickly find all news releases on a specific topic, please use the fulltext search.

Press Release Archive


Boehringer Ingelheim enrols first patients in pivotal Phase III interferon-free hepatitis C trial programme

- For media outside of the U.S.A., UK and Canada only

U.S. FDA Grants Priority Review to Boehringer Ingelheim’s Afatinib* NDA for EGFR Mutation-Positive Advanced NSCLC

- For NON-U.S. Media Only

Boehringer Ingelheim and Eli Lilly and Company announce positive top-line pivotal Phase III data results for empagliflozin

- EX US & UK. Medical Media Only.

Lilly reassumes sole worldwide development and commercialization rights for novel basal insulin analog


Boehringer Ingelheim receives EU approval for Metacam® for the relief of pain following dehorning in calves


Boehringer Ingelheim discontinues Phase II trial in patients with artificial heart valves

- For Non-US, Non-UK & Non-Canadian Media Only

Boehringer Ingelheim to initiate Phase III study in leukaemia with its compound volasertib* based on positive Phase II results

- For NON-US media only

Treatment with Pradaxa® associated with better patient outcomes after a major bleeding event compared to warfarin

- For Non-US, Non-UK & Non-Canadian Media Only

Boehringer Ingelheim and Apexigen sign manufacturing agreement for process development and early stage clinical supply


New Pradaxa® safety and efficacy data to be featured at ‘Best of ASH’ session

- For Non-US, Non-UK & Non-Canadian Media Only

Run for diabetes: Boehringer Ingelheim supports ‘Life for a Child’ programme on World Diabetes Day


Boehringer Ingelheim and BaroFold Announce Strategic Agreement on PreEMT™ High Pressure Protein Refolding Technology


Boehringer Ingelheim enters strategic collaboration agreement to support Molecular Partner’s proprietary pipeline with clinical supply of DARPin® molecules


Boehringer Ingelheim’s interferon-free all-oral hepatitis C treatment+ shows up to 85% viral cure in Phase IIb study including patients with advanced liver disease

- For media outside of the U.S.A., U.K. and Canada only

Recruitment complete for Trajenta® (linagliptin) cardiovascular outcome study in patients with Type 2 Diabetes

- For Non-U.S. and Non-U.K. Media

RELY-ABLE®: Unprecedented long-term data support safety profile and sustained efficacy of Pradaxa® for stroke prevention in AF

- For Non-US, Non-UK & Non-Canadian Media Only

Safety and efficacy of Pradaxa® (dabigatran etexilate) reconfirmed in clinical setting for VTE prevention after total knee or hip replacement


Pradaxa® - Development of antidote may expand range of methods to reverse anticoagulant effect during emergency situations

- For Non-US, Non-UK & Non-Canadian Media Only